Randall Richwine, DO
Family Medicine · Fort Worth, TXNPI 1710910740
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.2%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 59 manufacturers reported payments, led by Pfizer at 51.7% of the total. Reporting peaked in 2020 at $7,512 and has fallen 75.3% since, to $1,856 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 772 payments — averaging $39.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$16K
- Novo Nordisk$3K
- Sanofi-aventis U.S. LLC$2K
- AstraZeneca$1K
- AbbVie$972
- Boehringer Ingelheim$856
- plus $7K from 53 others
Across 144 payments — averaging $5305.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$407K
- Kowa Research Institute, Inc.$156K
- Exact Sciences$89K
- Bayer$55K
- Boehringer Ingelheim$27K
- Janssen Research & Development, LLC$17K
- plus $12K from 3 others
What the payments were for
- Consulting fees$6,98223%
- Speaking & faculty fees$9,03530%
- Travel & lodging$1,6045%
- Food & beverage$12,41541%
- Education$1100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$2,800
- RYBELSUS$1,890
- TZIELD$1,774
- FARXIGA$266
- SYMBICORT$266
- Nalu Neurostimulation System$145
- Kerendia$121
- NURTEC ODT$118
- BREZTRI AEROSPHERE$103
How this compares
$30,145 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 101 | $107,742 |
| OzempicSemaglutide | 71 | $92,739 |
| EliquisApixaban | 56 | $62,716 |
| XareltoRivaroxaban | 38 | $36,728 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $34,231 |
| RybelsusSemaglutide | 26 | $31,731 |
| FarxigaDapagliflozin Propanediol | 26 | $28,388 |
| MounjaroTirzepatide | 19 | $22,371 |
| TrulicityDulaglutide | 11 | $18,606 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $17,415 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $12,447 |
| Bydureon BciseExenatide Microspheres | 11 | $9,128 |
| Levemir FlexpenInsulin Detemir | 23 | $7,319 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $6,086 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 141 | $3,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $2,563 | $124,47097 claims |
| Boehringer IngelheimJardiance | $856 | $107,742101 claims |
| PfizerEliquis | $15,571 | $62,71656 claims |
| Lilly USA, LLCMounjaro, Trulicity | $738 | $40,97730 claims |
| Johnson & JohnsonXarelto | $115 | $36,72838 claims |
| AstraZenecaFarxiga, Symbicort | $1,057 | $34,47449 claims |
| GSKTrelegy Ellipta | $625 | $34,23145 claims |
| MerckJanumet | $195 | $17,41519 claims |
| AbbVieSynthroid | $972 | $1,38522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Fort Worth
- Robert CampbellFort Worth$318K
- Kenton MurthyFort Worth$40K
- Peter DamicoFort Worth$37K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.